Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Severe Head Trauma
Interventions
DRUG

AbelaDrug200

IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours

DRUG

mannitol

mannitol plus standard treatment

Trial Locations (3)

43210

RECRUITING

Ohio State University, Columbus

92868

RECRUITING

University of California, Irvine, Irvine

02118

ACTIVE_NOT_RECRUITING

Boston University Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Ohio State University

OTHER

collaborator

University of California, Irvine

OTHER

collaborator

Dr. Mahajan's Hospital & Industrial Trauma Centre

OTHER

lead

Abela Pharmaceuticals, Inc.

INDUSTRY